{{ session.Short }}
\r\n \r\n{{ session.Name }}
\r\n\r\n \r\n
\r\n
\n {{ $t(\"IndustryLandingPage.no_access\") }}
\n {{ $t(\"IndustryLandingPage.no_access_text\") }}\n
\n {{ exhibitorProduct.Description }}\n
\n\n\n
\n \n
\n
\n \n
\n
\n \n
\n
\n {{ $t(\"IndustryLandingPage.no_access\") }}
\n {{ $t(\"IndustryLandingPage.no_access_text\") }}\n
\n {{ $t(\"IndustryLandingPage.productshowreel_headline\") }}\n
\n\n {{ $t(\"IndustryLandingPage.productshowreel_subheadline\") }}\n
\n\n\r\n Please allow our symposium organizer to know that you were here
\r\n
\n {{ $t(\"IndustryLandingPage.no_access\") }}
\n {{ $t(\"IndustryLandingPage.no_access_text\") }}\n
![](\"../../assets/playerDefault.jpg\"/)
\n {{leadsModel.Description}}
\r\n{{leadsModel.Description}}
\r\n\r\nToday's & Tomorrow's Symposia Board
\n![\"\"](\"/eau2020/board-1.png\")
\n \n \r\n Would you like to share your contact details with the organizer or join as visitor?
\r\n
\r\n Bitte lassen Sie unserem Symposiumsveranstalter wissen, dass Sie hier waren
\r\n
\r\n Please allow our symposium organizer to know that you were here
\r\n
\r\n Gespeichert
\r\n
\r\n Saved
\r\n
![](\"/ean/teva/TEVA-logo_184x130px.png\"){kind=logo}
\n \n ![](\"/ean/teva/Ajovy_logo_184x130px.png\"){kind=logo}
\n ![](\"/ean/teva/Neurologybytes_Logo.png\"){kind=logo}
\n ![](\"/ean/teva/Teva_Medical_Affairs_logo.png\"){kind=logo}
\n Symposium and Expert Insights
\n#EANpartners
\n Tweets by Teva Europe\n\n Teva Pharmaceuticals has been developing and producing medicines to help improve people’s lives for more than a century. We are committed to being a global leader in generic and specialty medicines with a portfolio of 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day. They are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.\n
\n\n Teva has been treating CNS diseases for over thirty years, including Multiple Sclerosis (MS), Parkinson’s Disease (PD), Huntington’s Disease (HD) and Tardive Dyskinesia (TD). We are now among the first companies globally to launch a preventative treatment for migraine that has been featured in peer-reviewed publication, and is now launched in the United States and certain parts of Europe.\n
\n\n Thanks for joining us on the AJOVY virtual booth. As the only anti-CGRP with both quarterly and monthly dosing options, AJOVY can help your patients experience less migraine and more moments.1\n
\n\n To find out how, watch our campaign video for a quick overview of AJOVY or delve deeper with the AJOVY story. You can also find out if you’re a Master of Migraine with our knowledge checker.\n
\n\n When the current restrictions caused by COVID-19 are eased, we look forward to seeing you once again, face-to-face.\n
\n\nCGRP, calcitonin gene-related peptide
\n References: 1. AJOVY 225 mg solution for injection – Summary of Product Characteristics. TEVA GmbH, Ulm, Germany. 2. Ferrari MD et al. Lancet 2019; doi: 10.1016/S0140-6736(19)31946-4.\n
\n Find out how much you know when it comes to migraine and learn more about its preventive treatment
\n
\n Discover how AJOVY is helping to reduce the number of monthly migraine days, even in patients with difficult-to-treat migraine.1,2\n
\n\n\n
\n Get a quick overview of AJOVY and the benefits it offers in the treatment of migraine, including quarterly and monthly dosing options.1\n
\n\n\n
\n This year’s EAN is different, because the world is different. Luckily, technology means that while we can’t see you face-to-face, we can still bring you information on COPAXONE® and the benefits it could bring your patients living with relapsing multiple sclerosis (RMS).
\n\n Register now for free access to timely, scientific updates on migraine and MS.\n
\n\n
\n Explore the great variety of content we provide.\n
\n\n
\n Expand your knowledge with our in-depth articles and concise publication summaries.\n
\n\n
\n Stay up-to-date on new scientific perspectives from major neurology congresses.\n
\n\n
\n Watch live and on-demand webinars for the latest insights from your peers.\n
\n\n
\n Learn from world-renowned experts through our eLearning modules.\n
\n\n
\n Professor Messoud Ashina (Chair) introduces the symposium programme: Anti-CGRP monoclonal antibodies and the evolving migraine prevention landscape\n
\n \n \n\n Dr Michel Lanteri-Minet asks what is the true cost of migraine from a patient perspective\n
\n \n\n Dr Antoinette Maassen van den Brink reviews migraine pathophysiology and new insights for targeted prevention\n
\n\n Professor Uwe Reuter considers monitoring response to anti-CGRP therapy: which outcomes and how often? Including the latest fremanezumab data\n
\n \n\n Dr Gianluca Coppola
\n Do we really need more preventive therapies? Do monoclonal antibodies act centrally or peripherally? Do they cause an immune response? These questions and more are addressed!\n
\n Dr Gudrun Gossrau
\n We know that many people with migraine have depression but how does migraine severity relate to risk of psychiatric comorbidities, and what impact does depression have on migraine outcomes? Find out more!\n
\n Difficult-to-treat migraine
\n The FOCUS trial showed that fremanezumab can provide rapid and clinically significant improvements, even in those who had previously not responded to 2-4 classes of preventive medication\n
\n Difficult-to-treat migraine
\n The FOCUS trial showed that fremanezumab can provide rapid and clinically significant improvements, even in those who had previously not responded to 2-4 classes of preventive medication\n
\n
\n Chronic migraine
\n The HALO CM study demonstrated the efficacy of fremanezumab as a preventive therapy for patients with ≥15 headache days per month\n
\n Episodic migraine
\n The HALO EM study demonstrated the efficacy of fremanezumab as a preventive therapy for patients with <15 headache days per month\n
Fremanezumab is approved in Europe for prevention of migraine in adults who have ≥4 migraine days per month.
\n Fremanezumab may not be available in your country. Please consult local prescribing information before use.
\n ▼ This medicinal product is subject to additional monitoring
\n
\n Explore the neurovascular pathophysiology of migraine
\n From trigeminovascular activation to pain: the origins of a migraine attack are still not fully understood but what is our current understanding?\n
\n
\n Navigating the burden of migraine in Europe
\n True of false: migraine has a greater disability burden than Alzheimer’s and Parkinson’s disease? Watch or download to find out!\n
\n
\n Migraine prevention
\n Which patients should be considered for preventive therapy?\t\n
\n
\n Adherence
\n What factors drive low adherence and declining persistence to preventive therapies over time?\n
\n
\n Monoclonal antibodies
\n These therapies are playing an increasing role in migraine prevention. How do they differ from small molecules?\n
\n
\n Professor Per Soelberg Sørensen
\n DMT sequencing when treating MS is a key focus for physicians. But what is the current clinical guidance for MS management in the context of the COVID-19 pandemic?\n
\n Professor Magnhild Sandberg
\n What are the potential clinical approaches for managing women with MS who are planning a pregnancy and being treated with DMTs requiring washout?\n
\n Explore the use of glatiramer acetate in a patient with MS planning a pregnancy\n
\n \n \n\n US open-label extension
\n The longest clinical study to routinely and continuously evaluate the efficacy of any monotherapy in patients with RRMS for over 25 years\n
\n GALA open-label extension study
\n Treatment with GA40 over 7 years showed sustained efficacy and a consistent safety profile\n
Glatiramer acetate is indicated for the treatment of relapsing forms of multiple sclerosis.
\n Please consult local prescribing information before use.
{{ $t(\"IndustryLandingPage.no_company_description\") }}
\n![](\"/ean/Logo_VirtualCongress.svg\"){kind=logo}
\n ![](\"/ean/Logo_Header_EAN_neg.svg\"){kind=logo}
\n \n \r\n \r\n EULAR E-Congress will go live of on the 3rd of June 12:00 PM CEST\r\n
\r\n![](\"/eular2020/header_right.png\")
![\"Banner](\"/interplan2020/logo.png\"){kind=logo}
![\"Banner](\"/interplan2020/logo2.png\"){kind=logo}
![](\"/interplan2020/logoEAPD.jpg\")
\r\n ![](\"/interplan2020/logoDGKiZ.png\")
\r\n ![\"header\"](\"/espacehf2020/header.png\")
\r\n ![\"eau](\"/eau2020/eau.svg\")
\r\n ![\"\"](\"/eau2020/logo.png\"){kind=logo}
\r\n \r\n {{ $t(\"IndustryLandingPage.no_company_description\") }}
\n![](\"https://www.easd.org/virtualmeeting2020/images/Side-sicence-logo-white@2x.png\"){kind=logo}
\n \n \n Discover RYBELSUS® –\n The world’s first and\n only oral GLP-1 RA\n
\n \n\n Discover the\n mechanism of action\n of RYBELSUS®\n
\n \n\n Discover RYBELSUS®\n through five\n interactive questions\n
\n \n\n FOR HEALTHCARE PROFESSIONALS ONLY: The information contained in this site is intended for healthcare professionals only. This site is not intended to provide medical advice and/\n or treatment guidance. This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always\n refer to local materials such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of this\n information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice.\n
\n\n The Summary of Product Characteristics (SmPC) and abbreviated Prescribing Information (aPI)\n is based on the EU SmPC as of June 2020. Registration conditions differ internationally.\n Always refer to the full local SmPC before prescribing. As of September 2020, Rybelsus® is registered in the US, Canada, European Union (covering also Norway and Iceland), Switzerland,\n India and Japan.\n\n
\n\n Learn more about Ozempic® and\n how it can help your patient with type\n 2 diabetes and high CV risk\n
\n\n\n\n Listen to Dr. Adie Viljoen from East and\n North Hertfordshire NHS trust. UK\n
\n\n\n\n Discover how Tresiba® could help your patients with type 2 diabetes.\n
\n\n\n\n Dosing information for patients with type 2 diabetes starting on TRESIBA®\n
\n\n\n FOR HEALTHCARE PROFESSIONALS ONLY: The information contained in this site is intended for healthcare professionals only. This site is not intended to provide medical advice and/or treatment guidance. This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice.\n
\n\n The Summary of Product Characteristics (SmPC) and abbreviated Prescribing Information (aPI) is based on the EU SmPC as of April 2020. Registration conditions differ\n internationally. Always refer to the full local SmPC before prescribing.\n
\n\n FOR HEALTHCARE PROFESSIONALS ONLY: The information contained in this site is intended for healthcare professionals only. This site is not intended to provide medical advice and/or treatment guidance. This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice.\n
\n\n The Summary of Product Characteristics (SmPC) and abbreviated Prescribing Information (aPI) is based on the EU SmPC as of November 2018. Registration conditions differ\n internationally. Always refer to the full local SmPC before prescribing.\n
\n\n How reliably do your patients record their insulin dosing? Learn more about NovoPen®6 and NovoPen Echo® Plus.\n
\n\n Instead of making medical decisions based on\n manually recorded information, or none at all, you can\n know precisely how your patients have been taking\n their insulin, leading to more personalized, productive\n conversations about diabetes management.\n
\n\n\n\n With smart insulin pens, both you and your patients\n will have access to the reliable information you need\n to understand their personal insulin dosing habits and\n how they affect glucose levels.\n
\n\n\n The daily burden of diabetes disease management is high. So high, that people can feel frustrated and overwhelmed. At Novo Nordisk, we want to reduce some of this daily\n burden. So we are developing new digital solutions, beginning with smart insulin pens that can enable more personalized and productive conversations about diabetes\n management.\n
\n\n FOR HEALTHCARE PROFESSIONALS ONLY: The information contained in this site is intended for healthcare professionals only. This site is not intended to provide medical\n advice and/or treatment guidance. This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing\n any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the\n accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept\n this legal notice.\n
\n\n NovoPen®6 and NovoPen Echo® Plus are CE marked medical devices not available in Germany. NovoPen®6 and NovoPen Echo® Plus are planned to become available in a\n number of European countries starting later this year and throughout 2021. Time frames will vary according to device, insulin brand and unique market regulations.\n
\n\n Novo Nordisk Science Hub provides a comprehensive\n collection of digital features for EASD 2020 that\n supplement the materials available on EASD’s Virtual\n Meeting site. In addition to Novo Nordisk’s EASD\n abstracts and posters, you will find extra content—\n including audio poster tours, videos featuring our\n presenters and supplementary slide decks—for many\n of our presentations.\n
\n\n\n\n Please click on any of the links below to learn more\n about Novo Nordisk pipeline or to fill in the request\n form for any questions you may have, thank you!\n
\n\n\n\n Looking for engaging videos, tools and tips for daily\n diabetes management? Take a look at Novo Nordisk\n Patient Engagement Platform: Diabetes, What’s Next\n and explore the collection of articles written with and\n for people living with diabetes.\n
\n\n\n Explore with us at our Monday Corporate Symposium.\n
\n Broadcast live:\n\n Monday 21 September
\n 12.30-14.30 CET and then again at 16.00-18.00 CET\n
\n Delve deep into Obesity and CV risk through\n this insightful symposium.\n
\n Broadcast live:\n\n Wednesday 23 September
\n 18.45-19.45 CET\n
\n Join us for this symposium - with an exciting line up\n of talks around Insulin therapy.\n
\n Broadcast live:\n\n Thursday 24 September
\n 18.45-20.15 CET\n
\n Connect with top physicians in their\n discussion.\n
\n Broadcast live:\n\n Tuesday 22 September
\n 10.30-11.00 CET\n
\n Be part of an exciting discussion\n between top endocrinologist\n and cardiologist.\n
\n Broadcast live:\n\n Tuesday 22 September
\n 11.30-12.00 CET\n
\n Meet with us to get interesting insights\n on guidelines around NAFLD.\n
\n Broadcast live:\n\n Tuesday 22 September
\n 13.00-13.30 CET\n
\n Discuss with us at Insulin Meet the\n Expert.\n
\n Broadcast live:\n\n Wednesday 23 September
\n 14.00-14.30 CET\n
\n Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change\n to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering\n scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs\n about 43,500 people in 80 countries and markets its products in around 170 countries.\n For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube,\n
\n\n FOR HEALTHCARE PROFESSIONALS ONLY: The information contained in this site is intended for healthcare professionals only. This site is not intended to provide medical advice and/or treatment guidance. This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. This site contains scientific information presented at EASD 2020 and provided for the purpose of scientific exchange. This information may relate to data concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. Registration conditions vary internationally. Always refer to the Summary of Product Characteristics (product label), as approved by regulatory authorities in your country. It is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product, or serve as basis for any decision or action. By accessing this site and materials you accept this legal notice. HQ20G00039. Approved by September 2020\n
\nIf you choose to share your personal data with us, Novo Nordisk will process your personal data for the purpose of developing and maintaining a professional relationship with you as HCP as it is necessary for our legitimate interests.\n You may at any time request an overview of the personal data collected and processed and request correct and/or deletion of you personal data.\n You may exercise these rights including requesting us to stop or limit the processing of your personal data by contacting privacy@novonordisk.com.\n You can read more about the processing of your personal data and your rights in the Privacy Notice.
\n\n\n The content shown in Company Profile is intended for healthcare professionals only. Content about specific medicinal products is based on EU Summary of Product Characteristics (SmPC) Please consult the prescribing information in your country of practice as information may vary from country to country depending on local approvals. Individual products shown may not be registered in all countries worldwide, please consult the regulatory authority or Sanofi affiliate in your country for more information.\n
\n\n The content shown in Company Profile is intended for healthcare professionals only. Content about specific medicinal products is based on EU Summary of Product Characteristics (SmPC) Please consult the prescribing information in your country of practice as information may vary from country to country depending on local approvals. Individual products shown may not be registered in all countries worldwide, please consult the regulatory authority or Sanofi affiliate in your country for more information.\n
\n{{ $t(\"IndustryLandingPage.no_company_description\") }}
\n![](\"http://staging.dog.conference2web.com/images/Bild%20479@2x.png\")
\n \r\n {{ $t(\"IndustryLandingPage.no_access\") }}
\r\n {{ $t(\"IndustryLandingPage.no_access_text\") }}\r\n
\r\n {{ $t(\"IndustryLandingPage.no_access\") }}
\r\n {{ $t(\"IndustryLandingPage.no_access_text\") }}\r\n
![](\"../../../../assets/twitter-icon.png\"){kind=icon}
\n ![](\"../../../../assets/linkedin-icon.png\"){kind=icon}
\n ![](\"../../../../assets/instagram-icon.png\"){kind=icon}
\n ![](\"/ers2020/index-30.png\")
\n ![](\"/ers2020/index-pcc.png\")
\n ![](\"/ers2020/index-ep.png\")
\n ![](\"/ers2020/index-sic.png\")
\n ![](\"/ers2020/index-is.png\")
\n ![](\"/ers2020/index-wv.png\")
\n ![](\"/ers2020/index-cb.png\")
\n ![](\"/ers2020/AstraZeneca.png\")
\n ![](\"/ers2020/BoehringerIngelheim.png\")
\n ![](\"/ers2020/gsk.png\")
\n ![](\"/ers2020/NOVARTIS.png\")
\n ![](\"/ers2020/SANOFIGENZYMEREGENERON.png\")
\n ![](\"/ers2020/Roche.png\")
\n ![](\"/ers2020/ACTELION.png\")
\n ![](\"/ers2020/Chiesi.png\")
\n ![](\"/ers2020/CSLBehring.png\")
\n ![](\"/ers2020/Galapagos.png\")
\n ![](\"/ers2020/MENARINI.png\")
\n ![](\"/ers2020/MSD.png\")
\n ![](\"/ers2020/OLYMPUS.png\")
\n ![](\"/ers2020/ORIONPHARMA.png\")
\n ![](\"/ers2020/PHILIPS.png\")
\n ![](\"/ers2020/ResMed.png\")
\n ![](\"/ers2020/tevaRespiratory.png\")
\n